Compare · ANTM vs NTRA
ANTM vs NTRA
Side-by-side comparison of Anthem Inc. (ANTM) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTM and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ANTM is the larger of the two at $107.30B, about 3.4x NTRA ($31.34B).
- NTRA has hit the wire 10 times in the past 4 weeks while ANTM has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Anthem Inc.
- Natera Inc.
- Price
- $482.32+2.61%
- $218.63-2.05%
- Market cap
- $107.30B
- $31.34B
- 1M return
- -
- +5.91%
- 1Y return
- -
- +36.05%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 25
Anthem Inc.
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ANTM
- SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units
- SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units
- SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units
- SEC Form 4: Boudreaux Gail gifted 10,000 shares, decreasing direct ownership by 8% to 111,415 units
- Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4: Kendrick Charles Morgan Jr covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.54% to 14,450 units
- SEC Form 4: Haytaian Peter D covered exercise/tax liability with 200 shares, decreasing direct ownership by 2% to 11,961 units
- SEC Form 4: Strable-Soethout Deanna D was granted 200 shares
- SEC Form 3 filed by new insider Strable-Soethout Deanna D
- SEC Form 424B3 filed by Anthem Inc.
Latest NTRA
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $335,091 worth of shares (1,652 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 140,643 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $291,684 worth of shares (1,438 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 0.77% to 185,782 units (SEC Form 4) (withholding tax)
- Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
- Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
- Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
- Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
- CO-FOUNDER Sheena Jonathan sold $959,451 worth of shares (4,650 units at $206.33) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 252,502 units (SEC Form 4)
- Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)